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Introduction: Inflammatory bowel diseases (IBD) are complex multi-factorial diseases with increasing incidence
worldwide but their treatment is far from satisfactory. Unconventional strategies have consequently been investigated,
proposing the use of cells as an effective alternative approach to IBD. In the present study we examined the protective
potential of exogenously administered human umbilical cord derived mesenchymal stem cells (UCMSCs) against
Dextran Sulfate Sodium (DSS) induced acute colitis in immunodeficient NOD.CB17-Prkdc
scid/J mice with particular
attention to endoplasmic reticulum (ER) stress.
Methods: UCMSCs were injected in NOD.CB17-Prkdc
scid/J via the tail vein at day 1 and 4 after DSS administration.
To verify attenuation of DSS induced damage by UCMSCs, Disease Activity Index (DAI) and body weight changes
was monitored daily. Moreover, colon length, histological changes, myeloperoxidase and catalase activities,
metalloproteinase (MMP) 2 and 9 expression and endoplasmic reticulum (ER) stress related proteins were
evaluated on day 7.
Results: UCMSCs administration to immunodeficient NOD.CB17-Prkdc
scid/J mice after DSS damage significantly
reduced DAI (1.45 ± 0.16 vs 2.08 ± 0.18, p < 0.05), attenuating the presence of bloody stools, weight loss, colon
shortening (8.95 ± 0.33 cm vs 6.8 ± 0.20 cm, p < 0.01) and histological score (1.97 ± 0.13 vs 3.27 ± 0.13, p < 0.001).
Decrease in neutrophil infiltration was evident from lower MPO levels (78.2 ± 9.7 vs 168.9 ± 18.2 U/g, p < 0.01). DSS
treatment enhanced MMP2 and MMP9 activities (>3-fold), which were significantly reduced in mice receiving
UCMSCs. Moreover, positive modulation in ER stress related proteins was observed after UCMSCs administration.
Conclusions: Our results demonstrated that UCMSCs are able to prevent DSS-induced colitis in immunodeficient
mice. Using these mice we demonstrated that our UCMSCs have a direct preventive effect other than the T-cell
immunomodulatory properties which are already known. Moreover we demonstrated a key function of MMPs and
ER stress in the establishment of colitis suggesting them to be potential therapeutic targets in IBD treatment.* Correspondence: francescopaolo.russo@unipd.it
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Inflammatory bowel diseases (IBD) are complex multifac-
torial diseases showing increasing prevalence worldwide
[1]. The two principal conditions that involve inflamma-
tion of the intestine are ulcerative colitis and Crohn’s
disease. Ulcerative colitis involves the large intestine with
contiguous inflammation of the colonic lamina propria,
accelerated breakdown of extracellular matrix and disrup-
tion of the mucosal barrier [2,3], with an excessive pro-
duction of a variety of inflammatory mediators such as
proteolytic enzymes, cytokines, growth factors and react-
ive oxygen species (ROS) [2,4]. Recent studies link endo-
plasmic reticulum (ER) stress to the pathogenesis of IBD
[5,6]. ER stress arises from conditions that cause the accu-
mulation of misfolded or unfolded proteins within the ER
lumen.
ER stress induces activation of the unfolded protein
response (UPR), a signaling network that is required to
resolve stress, restoring ER homeostasis and promoting
cell survival and adaptation. Conversely, under unresolv-
able ER stress conditions, the UPR promotes inflamma-
tion and apoptosis. ER stress has a unique role in the
epithelium and can be both a primary cause as well as a
consequence of intestinal inflammation. The epithelial
cells of the gastrointestinal tract, because of their barrier
function, are exposed to toxins and infectious agents
that can adversely affect protein folding in the ER and
cause ER stress. Recent studies indicate that ER stress
could induce inflammation [6-10]. Inflammation can be
induced directly by UPR pathways in stressed cells, or
indirectly through interaction with immune cells re-
cruited by inflammatory cytokines released from stressed
cells [11]. Moreover, reduction of the effectiveness of the
mucosal barrier due to decreased secretion of antimicro-
bial molecules and mucins and premature apoptosis of
stressed cells could exacerbate the inflammatory envir-
onment typical of IBD.
Despite many advances in basic and clinical science
[12,13], treatment of IBD is unsatisfactory. Unconven-
tional strategies have consequently been investigated,
identifying the use of stem cells as an alternative ap-
proach to treating IBD. Mesenchymal stem cells (MSCs)
have emerged as a promising candidate for cellular ther-
apeutics for disorders caused by abnormal immune
responses due to their anti-inflammatory and reparative
properties [14-21]. Different mechanisms are postulated
to be involved in amelioration of colitis by administra-
tion of MSCs in animal models and in humans. The
principal findings link the amelioration of clinical signs
of colitis to local anti-inflammatory actions [19] through
suppressed expression of cytokines such as interferon
gamma, interleukin-23 and interleukin-17 [21,22].
The present study aimed to demonstrate whether um-
bilical cord mesenchymal stem cells (UCMSCs) have adirect action other than their T-cell immunomodulatory
effect in an experimental model of colitis. For this pur-
pose we induced experimental colitis in immunodefi-
cient mice by administration of dextran sulfate sodium
(DSS). The NOD.CB17-Prkdc
scid/J mice are character-
ized by the absence of functional T cells and B cells,
have impaired natural killer cell function and have
severe combined immunodeficiency. We focused on the
reduction in damaged epithelial barrier integrity, the re-
duction in inflammatory infiltration and the modulation
of the UPR.
Methods
Umbilical cord mesenchymal stem cells isolation and
expansion
Umbilical cord (UC) collection and processing were
approved by the Veneto Region Review Board (4087/03).
UC samples were obtained immediately after full-term
deliveries, after written informed consent from the mothers
at the Obstetrics and Gynaecology Unit of Cittadella
Hospital, Padova, Italy, and processed within 24 hours.
UCMSCs were isolated and expanded according to the
protocol reported previously by our group [14,23]. Briefly,
the umbilical vessels were manually removed and the
jelly was minced to obtain small fragments; these were
cultured in standard medium (Dulbecco’s modified
Eagle’s medium high glucose, fetal bovine serum 20%, 1%
glutamine, 1% penicillin/streptomycin). UCMSCs started
to migrate from the explants within 10 to 15 days.
In vitro characterization of UCMSCs
Cells were analyzed for UCMSCs surface marker expres-
sion using anti-human antibodies raised against CD73,
CD90, CD166, CD105, CD44, integrin β1 (CD29), c-kit
and human leukocyte antigens-DR (all from BD Biosciences,
San Diego, CA, USA). As negative controls, isotype anti-
bodies conjugated with fluorescein isothiocyanate and
R-phycoerythrin (Santa Cruz Biotechnology, Santa Cruz,
CA, USA) were used. The cytofluorimetric analyses were
performed with the MoFlo High-Speed Cell Sorter
(DAKO-Beckman Coulter, Carpinteria, CA, USA) and
data were analyzed using Summit 4.3 software (DAKO-
Beckman Coulter).
Mesenchymal stem cell features of UCMSCs were in-
vestigated by adipogenic and osteogenic differentiation
assays and their fetal origin was verified through sex-
determining region Y gene analysis, as described previ-
ously by our group [23].




scid/J male mice, 7 to 9
weeks old and weighing 18 to 25 g, were obtained from
Charles River Laboratories (Wilmington, MA, USA). The
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vidually and fed with an autoclaved pellet diet and water ad
libitum. All experiments were conducted in strict accord-
ance with the institutional guidelines for animal research
and approved by the Directorate-General for Animal
Health and Veterinary Drugs of the Italian Ministry of
Health in accordance with the law on animal experimen-
tation (DL 116/92, protocol number 76/2010/B, approval
date 7 April 2010). Furthermore, all animal treatments
were reviewed and approved in advance by the ethics
committee of the University of Padova, Italy.
Experimental acute colitis was induced in mice by oral ad-
ministration of 3.5% (wt/vol) DSS (TdB Consultancy AB,
Uppsala, Sweden) in sterile drinking water for 7 days. The
DSS (molecular weight ~40 kDa) solution was prepared
fresh daily. At day 1 after commencement of DSS treat-
ment, mice were randomly divided into two groups (n = 5)
and injected intravenously with either 1 × 106 cells in 100
μl phosphate-buffered saline (PBS) per animal (DSS +
UCMSCs group) or with 100 μl PBS alone (DSS group).
Healthy mice injected with UCMSCs via the tail vein
per time (UCMSCs group, n = 5) and healthy mice fed
with a normal diet and sterile water (negative control
group, n = 5) were used as controls.
Assessment of the severity of colitis and histological
examination
To examine the severity of colitis, stool consistency,
fecal bleeding and weight loss were each evaluated daily
on a 0 to 4 point scale and averaged for an overall dis-
ease activity index (DAI). On day 7, mice were anesthe-
tized by inhalation of isofluorane, blood samples were
collected by cardiac puncture and animals were then
sacrificed by cervical dislocation. The entire colon was
excised and carefully washed in PBS. Colon length was
measured before sectioning for specific analysis. Colonic
inflammation and damage were analyzed by histological
examination. Sections of the distal colon 1 cm long were
cut out longitudinally and fixed in 10% formalin for at least
24 hours and then embedded in paraffin wax for histo-
logical analysis. Distal colon sections 4 μm thick were
stained with hematoxylin and eosin to address the degree
of inflammation. The damage was scored blindly, with
slight modification, as reported by Iba and colleagues [24].
Staining of goblet cells and assessment of the collagen
deposition were performed by periodic acid–Schiff and
Masson’s trichrome staining respectively according to
the manufacturer’s protocol (Sigma Aldrich, Saint Louis,
MO, USA).
Scores for disease activity index calculation
The weight loss percentage was scored as: grade 0, none;
grade 1, 1 to 5%; grade 2, 5 to 10%; grade 3, 10 to 20%;
grade 4, >20%. Fecal bleeding was scored as grade 0, nobleeding; score 1, few blood-tinged stools; score 2, some
bleeding; grade 3, gross bleeding; grade 4, blood filling
the whole colon. The score for stool consistency was:
grade 0, normal stool; grade 1, slightly loose stool; grade
2, loose stools; grade 3, watery stool; score 4, severe
diarrhea (according to Cooper and colleagues [25], with
slight modifications).
Scores for histological analysis
The score for histological analysis was as follows: loss of
epithelium (0 = none; 1 = 0 to 5%, mild; 2 = 5 to 10%,
moderate; 3 = >10%, severe): crypt damage as percentage
loss of crypt (0 = none; 1 = 0 to 10%, mild; 2 = 10 to 20%,
moderate; 3= >20%, severe): depletion of goblet cells
(0 = none; 1 =mild; 2 =moderate; 3 = severe): and infiltra-
tion of inflammatory cells (0 = none; 1 =mild; 2 =moder-
ate; 3 = severe).
Localization of exogenously administered UCMSCs
Sections were stained with a standard immunohisto-
chemistry procedure with specific Anti-Human Nuclear
Antibody (MAB1281; Chemicon, Millipore Corporation,
Billerica, MA, USA) to identify the localization of ex-
ogenously administered UCMSCs in the colonic tissues.
No reactivity against mouse antigens was guaranteed by
the manufacturer.
Tissue myeloperoxidase assay and serum catalase assay
Myeloperoxidase (MPO) activity, an index of the inflam-
matory response, was assayed in colonic tissues as de-
scribed previously by Islam and colleagues [26]. Catalase
activity as an index of oxidative stress was measured on
serum samples employing the method of Chance and
Maehly [27]. The catalase activity was expressed as units
per milligram of protein, and units of enzyme activity is
defined as the amount of enzyme required to degrade 1
μmol H2O2 per second per milligram of protein.
Matrix metalloproteinase activity
Expression of matrix metalloproteinase (MMP)2 and
MMP9, which are well known to be involved in intes-
tinal disorders and IBD, was evaluated. Colonic tissues
were washed with cold PBS and tissues were lysed by
lysis buffer (0.05 M Tris, 0.2 M NaCl, 0.010 M CaCl2,
0.5% Triton X-100) for 20 minutes on ice. Cellular deb-
ris was removed by centrifugation and protein concentra-
tion was estimated using a BCA™ protein assay kit (Pierce
Diagnostics, Rockford, IL, USA) on the supernatant. Tis-
sue lysates were subjected to gelatin zymography [28].
Western blot analysis of endoplasmic reticulum stress markers
Colonic tissues were lysed in extraction buffer (100 mM
KCl, 3 mM NaCl, 3.5 mM MgCl2, and 10 mM HEPES;
pH 7.4) containing 1% Triton X-100, 1× Protease Inhibitor
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(1,500 × g for 30 minutes at 4°C). Protein concentration
was determined in the supernatant using the BCA™ pro-
tein assay kit (Pierce Diagnostics). SDS-PAGE and transfer
to nitrocellulose membranes was performed using stand-
ard procedures. Membranes were analyzed for the expres-
sion of specific markers of ER stress activation: the ER
stress chaperone binding immunoglobulin protein (BiP),
the ER stress sensor PKR-like endoplasmic reticulum
kinase (PERK) and the protein disulfide isomerases (PDI)
according to the manufacturer’s protocol (Cell Signaling
Technology, Inc., Danvers, MA, USA). Images were ac-
quired and digitally scored with a densitometer image
analyzer (Quantity one; Bio Rad, Hercules, CA, USA).
Statistical analyses
Data are presented as the mean ± standard deviation. Stu-
dent’s t test was used to assess differences between groups.
P <0.05 was assumed to indicate a significant difference.
Data analyses were performed with SPSS (IBM Corp.,
Armonk, NY, USA) and StatsDirect (Altrincham, UK).
Results
Umbilical cord mesenchymal stem cells isolation and
phenotype analysis
UCMSCs started to migrate from the explants within 10
to 15 days and gave rise to a homogeneous population of
adherent spindle-shaped cells with a fibroblastic morph-
ology. These cells fulfill the minimal criteria for definingFigure 1 Cellular characterization of umbilical cord mesenchymal stem cel
showed a mesenchymal phenotype. Cells were positive for typical mesenc
hematopoietic markers (CD44 and c-kit) were weakly or not expressed. HumMSCs as reported by the International Society for Cellular
Therapy [29]. Indeed, in agreement with our previous
studies [14,23], flow cytometry analysis showed high
expression of typical mesenchymal cell markers such as
CD166, CD105, CD90, CD73 and CD29. Hematopoietic
and endothelial markers CD44 and c-kit were weakly or
not expressed and human leukocyte antigen-DR was not
expressed at all (Figure 1). Moreover, UCMSCs were able
to differentiate toward adipogenic and osteogenic lineages
(as reported previously by our group [23]).
Umbilical cord mesenchymal stem cells reduce disease
severity in DSS-induced colitis
In NOD.CB17-Prkdc
scid/J mice, administration of 3.5%
DSS for 7 days induced severe colitis localized mainly in
the distal colon. All DSS-treated mice developed disease
symptoms similar to colitis in humans, including body
weight loss, bloody diarrhea and shortening of the colon
with a progressive increase of the DAI, which included
scores of weight loss, stool consistency and fecal bleeding.
UCMSCs administration at days 1 and 4 in DSS-
treated mice improved all of the disease parameters.
DAI scores, calculated daily, were lower in these mice
compared with those treated with DSS alone throughout
the 7 days of observation and these reductions were
significant at days 4, 6 and 7 (P <0.05 at day 4, P <0.01
at day 6 and P <0.0001 at day 7) (Figure 2A).
Moreover, DSS mice treated with UCMSCs did not
suffer the same degree of DSS-induced colon shorteningls. Flow cytometry analysis of umbilical cord mesenchymal stem cells
hymal markers (CD29, CD73, CD90, CD105 and CD166) while














































Figure 2 Clinical and therapeutic efficacy of exogenous umbilical cord mesenchymal stem cell administration. (A) Disease activity index (DAI). In
the umbilical cord mesenchymal stem cells (UCMSCs)-treated group, the DAI score was significantly downregulated on days 4, 6 and 7 of treatment.
(B) Colon length. UCMSCs in dextran sulfate sodium (DSS)-treated mice were able to reduce the degree of DSS-induced colon shortening compared

















Figure 3 Therapeutic efficacy of umbilical cord mesenchymal stem cell treatment on the histological colitis score. Administration of umbilical
cord mesenchymal stem cells (UCMSCs) in dextran sulfate sodium (DSS)-treated mice significantly improved histological scores. Values reported
as mean ± standard deviation. ***P <0.001.
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respectively, P <0.01; Figure 2B). Control group mice
did not show any signs of colitis and gained weight over
time.
Colitic mice treated with DSS showed disordered mu-
cosal architecture with loss of crypts, diffuse depletion
of goblet cells, inflammatory cell infiltration, edema and
epithelial cell necrosis. In contrast, the colonic tissue
from DSS + UCMSCs-treated animals showed a signifi-
cant reduction of histological score (1.97 ± 0.13 vs. 3.27
± 0.13, P <0.001; Figure 3) with only focal depletion of
goblet cells, and less inflammatory cell infiltration within
the lamina propria (Figure 4).
To investigate whether the marked rigidity found in
the distal colon of DSS-treated mice was due to inflam-
mation/infiltration or fibrosis, Masson’s trichrome stain-
ing for collagen deposition was performed.Figure 4 Histological analysis of the distal colon on day 7 of control mice
cell-treated mice, DSS + phosphate-buffered saline-treated mice and DSS +
eosin (H&E) staining showed improvement after umbilical cord mesenchym
inflamed area, crypt damage, edema of submucosa and infiltration of inflam
that displayed a strong purple/magenta color when stained with PAS reag
dextran sulfate sodium (DSS) + phosphate-buffered saline mice. In contrast,
trichrome staining showed increased deposition of collagen after DSS treatCollagen deposition, evident as blue/green color staining
in the mucosa and submucosa, was more marked in DSS
mice compared with controls, presumably contributing to
the increased rigidity of the inflamed region. In contrast,
the degree of collagen deposition was greatly reduced in
both mucosa and submucosa of the DSS +UCMSCs group
(Figure 4).Umbilical cord mesenchymal stem cells localize to the
colon of DSS-treated mice
To study whether UCMSCs could be found in the
DSS-damaged colon, immunohistochemical analysis
for human nuclei was performed. UCMSCs were detected
in the inflamed distal colon of colitic mice (Figure 5), but
not in the colons of healthy mice infused with UCMSCs
(Figure 5).(no dextran sulfate sodium (DSS)), umbilical cord mesenchymal stem
umbilical cord mesenchymal stem cell-treated mice. Hematoxylin and
al stem cell (UCMSCs) treatment because it reduced the extent of the
matory cells. Periodic acid–Schiff (PAS) staining detected goblet cells
ent. There was complete depletion of goblet cells in the crypts of the
DSS + UCMSCs mice showed retention of some goblet cells. Masson’s
ment (blue/green-stained areas represent collagen deposits).
Figure 5 Localization of exogenously administered umbilical cord mesenchymal stem cells. Immunohistochemical analysis of the inflamed colon
in umbilical cord mesenchymal stem cell (UCMSCs)-treated mice compared with control mice. Human nuclei of UCMSCs were observed in the
lamina propria of colon of dextran sulfate sodium (DSS)-treated mice (red arrows), whereas no such human nuclei were observed in the
control mice.
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inflammatory tissue infiltration but do not influence
antioxidant activity
MPO activity was used as a measure of inflammation in-
duced by innate immunity, and was found to be signifi-
cantly increased (P <0.001) by DSS treatment at day 7
(168.95 ± 18.22 U/g vs. 63.46 ± 13.46 U/g in control
mice). Compared with the DSS colitic mice, the MPO
activity in the colon of DSS + UCMSCs animals was sig-
nificantly lower (78.23 ± 9.71 U/g vs. 168.95 ± 18.22 U/g,
P <0.01; Figure 6A). These data suggest that the
UCMSCs infusion inhibits DSS-induced tissue inflam-
matory infiltration.
To estimate the level of induced oxidative stress, cata-
lase activity was measured in the serum. A significant re-
duction in the activity of catalase was observed in the
colon of DSS-treated mice compared with controls, indi-
cating the exhaustion of antioxidant enzymes. Administra-
tion of UCMSCs in DSS-treated mice failed to maintain
the initial level of catalase activity (1.53 ± 0.20 vs. 1.19 ±
0.07 in DSS mice; Figure 6B).MMP2 and MMP9 expression in the colon
MMPs are extracellular proteinases with proteolytic
activity against extracellular matrix proteins. We ex-
amined MMP2 and MMP9 activities that are reported
to be involved in IBDs. Colons of control mice showed
low MMP2 and MMP9 activity as measured by gelatin
zymography. Treatment with DSS induced a signifi-
cant upregulation in activities of both MMPs, while
activities in DSS + UCMSCs animals were significantly
lower, at levels comparable with controls (P <0.001)
(Figure 7).Umbilical cord mesenchymal stem cells modulate the
expression of endoplasmic reticulum stress proteins
Given the evidence for a role of ER stress proteins in in-
testinal diseases, we measured the expression of specific
proteins of the UPR pathway. To study the three princi-
pal phases of UPR (initiation, signal transduction and
downstream effect) we measured expression of: BiP, a
chaperone that has been extensively used as biological
marker for onset of the UPR; the major transducer of
the ER stress response protein kinase PERK; and the
UPR-induced foldase PDI. Analysis of these markers
showed a significant induction in the distal colon that
coincided with the clinical and histological signs of
DSS-induced colitis. Administration of UCMSCs induced
a significant reduction in the amount of BIP and PDI that
was comparable with controls (P <0.001). On the contrary,
PERK expression was not affected by UCMSCs administra-
tion (Figure 8).Discussion
Cellular therapy with stem cells and their progeny is a
promising new approach capable of addressing as yet
unmet medical needs in various inflammatory and auto-
immune diseases [30]. Recent studies provide ample evi-
dence that MSCs can promote regeneration of wounded
tissues, modulate the systemic immune system and have
anti-inflammatory properties [22,31-33]. Our present
and past data clearly demonstrate that human UC from
full-term deliveries can be successfully used as a source
of MSCs due to their ease of isolation and reproducibil-
ity to obtain significant numbers of cells. UCMSCs are
plastic adherent and highly proliferative cells, and also











































Figure 6 Cytotoxicity study of myeloperoxidase activity in the colon and catalase activity in serum. Cytotoxicity studies were performed by
measuring (A) myeloperoxidase activity in the colon and (B) catalase activity in serum. Mice receiving dextran sulfate sodium (DSS) + umbilical
cord mesenchymal stem cell (UCMSCs) treatment showed a significantly reduced myeloperoxidase activity compared with the DSS + phosphate-
buffered saline (PBS) group (**P <0.01). On the other hand, DSS + UCMSCs-treated mice had almost similar catalase levels to the DSS + PBS mice.
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for Cellular Therapy [29].
The beneficial effects of MSCs have been mostly at-
tributed to paracrine effects, the release of signaling fac-
tors for tissue repair, rather than transdifferentiation or
fusion with cells in injured areas [34]. These paracrine
effects have been attributed to immunosuppressive cy-
tokines that modulate immune responses by inhibiting
the effector T-cell responses and by increasing the num-
ber of T-regulatory cells [22,35]. Currently, the precise
mechanisms by which MSCs act remain unclear, but
MSCs seem to have effects at multiple levels, not just in
a single immune response pathway.
In the present study we aimed to assess whether
UCMSCs have a direct therapeutic effect other than
their T-cell immunomodulatory effect. We evaluated the
effects of exogenously administered UCMSCs in DSS-
induced acute colitis in an experimental mouse model ofimmunodeficiency. In this way we aimed to exclude the
previously assessed T-cell immunomodulatory contribu-
tion of MSCs in chemically induced colitis in mice. To
this end we used NOD.CB17-Prkdc
scid/J mice, which are
characterized by absent functional T cells and B cells,
have impaired natural killer cell function and have se-
vere combined immunodeficiency. Our results are in line
with previous reports which have shown that DSS in-
duces colitis in immunodeficient mice independently of
T lymphocytes and B lymphocytes [36,37]. DSS adminis-
tered orally is the cause of epithelial cell toxicity, increased
intestinal permeability and macrophage activation. More-
over, recent studies demonstrated by selective knockout of
a specific UPR protein that ER stress is a critical player in
DSS-induced colitis [38-40]. These elegant studies demon-
strated by selective knockout of a specific gene of the UPR
pathway that ER stress is a major component of the cas-


























Figure 7 Gelatin zymograms (7.5% SDS-PAGE) showing matrix metalloproteinase activity in the colon. Matrix metalloproteinase MMP2 (A) and
MMP9 (B) activity in the colon. The densitometric intensity of bands is shown in the bar graphs. There was elevated expression of both MMP2
and MMP9 in the dextran sulfate sodium (DSS) + phosphate-buffered saline mice compared with controls, and there was significantly less expression
in the DSS + umbilical cord mesenchymal stem cells (UCMSCs) mice (***P <0.001). Values are mean ± standard deviation of three independent
experiments. a.u., arbitrary units.
Banerjee et al. Stem Cell Research & Therapy  (2015) 6:79 Page 9 of 14Taken together these events induce the deleterious effects
of DSS, although the specific mechanisms are not fully
understood.
We demonstrated that the dose selected (3.5% DSS
40 kDa for 7 days) was capable of inducing acute colitis
in immunodeficient NOD.CB17-Prkdc
scid/J mice with de-
finitive clinical signs such as diarrhea, gross rectal bleeding
and loss of body weight. The lesions induced by DSS were
characterized by crypt distortion or entire crypt loss by
day 7, complete loss of goblet cells and collagen depos-
ition. The damage compromised normal colonic function
and led to loss of body weight and an increase in the DAI
score.
In this study the systemic administration of UCMSCs
at day 1 and day 4 led to a significant reduction ofdisease activity, apparent from day 2, and to an amelior-
ation of the histological score with reduction both in
submucosa edema and collagen deposition. The fact that
this significant amelioration occurred in such a short
time frame suggests that UCMSCs have beneficial effects
through paracrine activity, rather than through cell dif-
ferentiation or cell fusion. This hypothesis is supported
by the very rapid cell turnover in the intestine.
Interestingly, an increased incidence of goblet cells,
which is generally associated with regeneration during
the recovery phase of DSS colitis, was also observed at
day 7 in those mice also treated with UCMSCs. This
might be an indication of less damage resulting in a
more normal transit time from the stem cell zone to the











































Control DSSUCMSCs DSS+UCMSCs ***
***
Figure 8 Western blot analysis of the endoplasmic reticulum stress response in the colon of control and treated mice. The densitometric analysis
showed a significant decrease in binding immunoglobulin protein (BIP) and protein disulfide isomerases (PDI) in the dextran sulfate sodium
(DSS) + umbilical cord mesenchymal stem cells (UCMSCs) mice when compared with the DSS + phosphate-buffered saline mice. (***P <0.001).
β-actin was used as a loading control. The densitometric intensity of bands is shown in the bar graphs. Values are mean ± standard deviation of
three independent experiments. a.u., arbitrary units; PERK, PKR-like endoplasmic reticulum kinase.
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probably because of the accelerated turnover of the re-
generating crypts resulting in insufficient time for goblet
cell differentiation.
Several studies have shown a correlation between an
increase in ROS production and disease activity in in-
flamed biopsies of IBD patients [41,42]. Recent studies
have linked intestinal oxidative stress to epithelial dam-
age. ROS are generated inside the intestinal tract during
the oxidative burst by activated phagocytic cells which
possess ROS-producing enzymes such as nicotinamide
adenine dinucleotide phosphate hydrate oxidase, nitric
oxide synthase and MPO [43].
In the present study we focused our attention on
MPO, an enzyme found predominantly in neutrophils
and which is a good marker of inflammatory cell infiltra-
tion and tissue injury. Indeed, neutrophil infiltration into
the inflamed mucosa is one of the most prominent histo-
logical features observed in IBD [44]. From our results,
the decrease of MPO activity after UCMSCs administration
can be explained by a reduction of DSS-induced neutrophil
accumulation in inflamed tissue.
Antioxidant enzymes, including catalase, represent the
first line of defense against free radicals, and therefore
their regulation depends mainly upon the oxidant status
of the tissue. In line with the enhanced activity of MPO
in DSS-treated mice, we showed a significant reduction in
catalase activity compared with control groups, indicatingtheir likely saturation to block DSS-induced massive free
radical production. However, UCMSCs in DSS colitis did
not influence the activity of catalase, which was similar to
that for the DSS-treated mice.
MMPs are a family of proteases involved in turnover
of extracellular matrix and cell migration and they have
been implicated as one of the main factors involved in
the process of tissue destruction and remodeling as well
as inflammation in IBD [3,45]. Indeed, MMPs could be
released from inflamed intestinal epithelial cells with
subsequent loss of mucosal integrity, thus facilitating
penetration of inflammatory cells into the colon. An im-
balance between degradative and reparative processes of
the extracellular matrix can induce crypt damage [46].
While the role of MMPs in pathogenesis of IBD is well
known, which MMPs are involved is still controversial.
Heimesaat and colleagues demonstrated that MMP2 and
MMP9 are involved in DSS-induced colitis but while
MMP2 is crucial in the pathogenesis of colitis, MMP9
seems not to be essential [47]. On the other hand,
Castaneda and colleagues demonstrated that MMP-9−/−
mice exposed to DSS or salmonella had a significantly re-
duced severity of colitis [48]. However, other groups have
demonstrated that other forms of MMPs alter the nature
of DSS-induced colitis. For example Park and colleagues
indicated that MMP3 and MMP9 are the principal MMPs
[49], while Koelink and colleagues ascribed the crucial
role to MMP8 and MMP9 [50]. Given the heterogeneity
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studied metalloproteinases: MMP2 and MMP9. During
IBD, MMP2 is highly upregulated and localizes to the
subepithelial and pericryptal fibroblasts/myofibro-
blasts, mononuclear cells (macrophages and lympho-
cytes), epithelial cells and vascular endothelial cells,
while MMP9 is expressed by immune cells (neutro-
phils, macrophages, lymphocytes) as well as by epithe-
lial cells during inflammation [51]. Our zymograms
illustrated that MMP2 and MMP9 were active in the
colonic homogenates from the DSS-treated mice. UCMSCs
transplantation was able to reduce or block expression
of both MMPs, thereby decreasing the protease burden
at the site of inflammation and thus maintaining the
mucosal integrity, preventing tissue degradation and
migration of inflammatory cells into the colon. A pos-
sible explanation for this comes from the study of
Lozito and Tuan [52], which demonstrated that MSCs
caused inhibition of MMPs by secreting high levels of
the MMP endogenous inhibitors, the tissue inhibitors
of metalloproteinases.Figure 9 Action of dextran sulfate sodium in immunodeficient mice and r
colitic mice. (A) Mechanism of action of DSS in immunodeficient mice and
(UCMSCs) in colitic mice. Dextran sulfate sodium (DSS) administration in im
metalloproteinase (MMP) activation and endoplasmic reticulum (ER) stress.
between apoptosis and proliferation, causing relevant leaks in the epithelia
macrophages produce reactive oxygen species (ROS) that lead to cell deat
stimuli that triggers ER stress. All of these events involving MMP activation
clinical signs comparable with inflammatory bowel diseases in humans, bu
natural killer cells. UCMSCs administration in colitic mice is able to reduce M
inflammation. Consequently, ROS production is lower and the vicious cycle
prevent DSS-induced colitis. MSC, mesenchymal stem cell.We then focused on determining whether UCMSCs
administration could affect the UPR due to ER stress in-
duced by DSS. As reported above, ER stress is crucial in
establishment of DSS-induced colitis [38], but the mech-
anism by which DSS induces ER stress is not known. It
was proposed that DSS alters the expression of tight
junctions and induces increased epithelial apoptosis and
the imbalance between apoptosis and proliferation causes
relevant leaks in the epithelial barrier, with consequently
inflammation and ER stress [53]. Bertolotti and colleagues
also suggested that DSS acts on the epithelial cells which
are the first to be exposed to the luminal contents, estab-
lishing a cascade of processes that leads to inflammation
and ulceration [40]. The observation that the onset of in-
flammation precedes the development of ulcerative lesions
[54,55] suggests that the direct toxicity of DSS resulting in
death of epithelial cells is unlikely to account for the
initiation of disease. The authors suggested that a DSS-
induced perturbation in ER function (ER stress) plays an
early role in the development of inflammation and subse-
quent ulceration. Given these findings, we evaluatedole of administration of umbilical cord mesenchymal stem cells in
(B) role of administration of umbilical cord mesenchymal stem cells
munodeficient mice induces integrin degradation, matrix
These events induce increased epithelial apoptosis and the imbalance
l barrier, with consequent inflammation. Infiltrating neutrophils and
h and further tissue damage. Moreover, ROS is one of the important
and ER stress presumably lead to the establishment of colitis with
t without the participation of T lymphocytes, B lymphocytes and
MP and ER activation, resulting in less epithelial degradation and
of epithelial damage is inhibited. In this way, UCMSCs are able to
Banerjee et al. Stem Cell Research & Therapy  (2015) 6:79 Page 12 of 14protein expression of three mediators of the UPR: BiP, a
chaperone that has been extensively used as biological
marker for onset of the UPR; PERK, the major transducer
of the ER stress response; and a UPR-induced foldase PDI.
Expression of all markers was greatly increased in DSS
colitic mice compared with control mice. After adminis-
tration of UCMSCs we observed a significant reduction in
the expression of BIP and PDI that reached a level com-
parable with control mice, but PERK expression was not
affected by UCMSCs administration. The cytoplasmic
portion of PERK contains a protein kinase domain,
which undergoes activating transautophosphorylation
by oligomerization in ER-stressed cells. Unfortunately,
the antibody we used for our western blot analysis did
not distinguish between PERK in its unphosphorylated
inactive form and the phosphorylated active form. Simi-
lar expression of PERK in DSS colitic mice and UCMSCs
+ DSS mice could therefore be due to this lack of discrim-
ination between the two forms.
Conclusions
Our results confirm that NOD.CB17-Prkdc
scid/J mice
are susceptible to acute DSS colitis, suggesting that T
cells, B cells and natural killer cells are not required for
disease onset, and that the acute disease may be driven
more by neutrophils or other innate immune cell types,
in line with previous reports [36,37]. Interestingly we
found a vicious cycle induced by DSS administration in
immunodeficient mice that included MMP activation,
neutrophil infiltration, ROS production and ER stress.
Neutrophils are one of the major cells responsible for
ROS production and it is known that excessive ROS ini-
tiates perturbation of the cellular redox balance leading
to cell death and further tissue damage [56]. Moreover,
ROS are one of the important stimuli that trigger ER
stress [57] and ER stress is often accompanied by in-
creased ROS generation [58] in the so-called paradigm
ROS-dependent ER stress. All of these events involving
MMP activation and ER stress presumably lead to the
establishment of colitis with clinical signs comparable
with IBD in humans, but without the participation of T
lymphocytes, B lymphocytes and natural killer cells
(Figure 9A). On the basis of these results, MMP and
ER stress inhibitors could be considered as potential
therapeutic targets in IBD treatment.
Our study demonstrated that the systemic infusion of
UCMSCs successfully ameliorated the clinical and histo-
logical signs of DSS-induced colitis. The reduction of
the DAI within 2 days of DSS treatment suggests that
the UCMSCs prevent the development of colitic damage
through a paracrine mechanism.
In conclusion, our results demonstrate that UCMSCs
are able to prevent DSS-induced colitis in immuno-
deficient mice. Using these mice we demonstratedthat our UCMSCs have a direct preventative effect
other than through T-cell immunomodulation (Figure 9B).
Moreover, our results strongly implicate MMPs and
ER stress in the establishment of colitis, suggesting
them to be potential therapeutic targets for IBD
treatment.
Abbreviations
BiP: binding immunoglobulin protein; DAI: disease activity index;
DSS: dextran sulfate sodium; ER: endoplasmic reticulum; IBD: inflammatory
bowel diseases; MMP: matrix metalloproteinase; MPO: myeloperoxidase;
MSC: mesenchymal stem cell; PBS: phosphate-buffered saline; PDI: protein
disulfide isomerases; PERK: PKR-like endoplasmic reticulum kinase;
ROS: reactive oxygen species; UC: umbilical cord; UCMSCs: umbilical cord
mesenchymal stem cells; UPR: unfolded protein response.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
AB and DB designed the study and wrote the paper. AB, DB, RDL, SP,
DA, MC, CMAP and AC carried out the experimental studies. PBo
coordinated the collection of human umbilical cord samples and
helped to draft the manuscript. MTC, PPP, MRA and GCS were involved
in drafting the manuscript or revising it critically for important
intellectual content. RD-I, PBu and FPR conceived the study, drafted the
manuscript and gave final approval of the version to be published.
MRA also gave final approval of the version to be published. All
authors read and approved the final manuscript.
Acknowledgements
The authors are grateful to the Roberto Farini Association ONLUS, the Marina
Minnaja Foundation ONLUS and COPEV (Comitato per la Prevenzione
dell’Epatite Virale) for funding the whole experiment.
Author details
1Department of Surgery, Oncology and Gastroenterology,
Gastroenterology/Multivisceral Transplant Unit, University Hospital
Padova, Via Giustiniani 2, Padova 35128, Italy. 2Department of
Pharmaceutical and Pharmacological Sciences, University of Padova, Via
Marzolo 5, 35131 Padova, Italy. 3Venetian Institute of Molecular
Medicine (VIMM), Via Orus, 2 35129 Padova, Italy. 4Obstetrics and
Gynecology Unit, Cittadella Hospital, via Casa di ricovero, 40 35013
Cittadella, Padova, Italy. 5Centre for Tumour Biology, Barts Cancer
Institute, Charterhouse Square, London EC1M 6BQ, UK.
Received: 24 September 2014 Revised: 26 September 2014
Accepted: 1 April 2015
References
1. M’Koma AE. Inflammatory bowel disease: an expanding global health
problem clinical medicine insights. Gastroenterology. 2013;6:33–47.
2. Herias MV, Koninkx JFJG, Vos JG, Huis in’t Veld JHJ, Van Dijk JE. Probiotic
effects of Lactobacillus casei on DSS-induced ulcerative colitis in mice. Int J
Food Microbiol. 2005;103:143–55.
3. Baugh MD, Perry MJ, Hollander AP, Davies DR, Cross SS, Lobo AJ, et al.
Matrix metalloproteinase levels are elevated in inflammatory bowel disease.
Gastroenterology. 1999;117:814–22.
4. Torres MI, Ríos A. Current view of the immunopathogenesis in inflammatory
bowel disease and its implications for therapy. World J Gastroenterol.
2008;14:1972–80.
5. Zhang K, Shen X, Wu J, Sakaki K, Saunders T, Rutkowski DT, et al.
Endoplasmic reticulum stress activates cleavage of CREBH to induce a
systemic inflammatory response. Cell. 2006;124:587–99.
6. McGuckin MA, Rajaraman DE, Das I, Lourie R, Florin TH. ER stress and the
unfolded protein response in intestinal inflammation. Am J Physiol
Gastrointest Liver Physiol. 2010;298:820–32.
7. Eri RD, Adams RJ, Tran TV, Tong H, Das I, Roche DK, et al. An
intestinal epithelial defect conferring ER stress results in inflammation
Banerjee et al. Stem Cell Research & Therapy  (2015) 6:79 Page 13 of 14involving both innate and adaptive immunity. Mucosal Immunol.
2011;4:354–64.
8. Garg AD, Kaczmarek A, Krysko O, Vandenabeele P, Krysko DV, Agostinis P. ER
stress-induced inflammation: does it aid or impede disease progression?
Trends Mol Med. 2012;18:589–98.
9. Osorio F, Tavernier SJ, Hoffmann E, Saeys Y, Martens L, Vetters J, et al. The
unfolded-protein-response sensor IRE-1alpha regulates the function of
CD8alpha + dendritic cells. Nat Immunol. 2014;5:248–57.
10. Shenderov K, Riteau N, Yip R, Mayer-Barber KD, Oland S, Hieny S,
et al. Cutting edge: endoplasmic reticulum stress licenses
macrophages to produce mature IL-1beta in response to TLR4
stimulation through a caspase-8- and TRIF-dependent pathway. J
Immunol. 2014;92:2029–33.
11. Guo B, Li Z. Endoplasmic reticulum stress in hepatic steatosis and
inflammatory bowel diseases. Front Genet. 2014;5:242.
12. Baumgart DC, Carding SR. Inflammatory bowel disease: cause and
immunobiology. Lancet. 2007;369:1627–40.
13. Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects
and established and evolving therapies. Lancet. 2007;369:1641–57.
14. Burra P, Arcidiacono D, Bizzaro D, Chioato T, Di Liddo R, Banerjee A, et al.
Systemic administration of a novel human umbilical cord mesenchymal
stem cells population accelerates the resolution of acute liver injury. BMC
Gastroenterol. 2012;12:88–96.
15. Russo FP, Parola M. Stem and progenitor cells in liver regeneration and
repair. Cytotherapy. 2011;13:135–44.
16. Burra P, Tomat S, Bizzaro D, Pellicanò D, Masier A, Conconi MT, et al. Stem
cells in hepatology. Organs Tissues Cells. 2008;1:15–22.
17. Burra P, Bizzaro D, Ciccocioppo R, Marra F, Piscaglia AC, Porretti L, et al.
Therapeutic application of stem cells in gastroenterology: an up-date. World
J Gastroenterol. 2011;17:3870–80.
18. Alison MR, Lin WR, Lee CY, Poulsom R, Wright NA, Otto WR. The ailing
gut: a therapeutic role for bone marrow cells? Transplantation.
2012;93:565–71.
19. Parekkadan B, Upadhyay R, Dunham J, Iwamoto Y, Mizoguchi E, Mizoguchi
A, et al. Bone marrow stromal cell transplants prevent experimental
enterocolitis and require host CD11b + splenocytes. Gastroenterology.
2011;140:966–75.
20. He XW, He XS, Lian L, Wu XJ, Lan P. Systemic infusion of bone marrow-derived
mesenchymal stem cells for treatment of experimental colitis in mice. Dig Dis
Sci. 2012;57:3136–44.
21. Liang L, Dong C, Chen X, Fang Z, Xu J, Liu M, et al. Human umbilical cord
mesenchymal stem cells ameliorate mice trinitrobenzene sulfonic acid
(TNBS)-induced colitis. Cell Transplant. 2011;20:1395–408.
22. Tanaka F, Tominaga K, Ochi M, Tanigawa T, Watanabe T, Fujiwara Y, et al.
Exogenous administration of mesenchymal stem cells ameliorates dextran
sulfate sodium-induced colitis via anti-inflammatory action in damaged
tissue in rats. Life Sci. 2008;83:771–9.
23. Conconi MT, Burra P, Di Liddo R, Calore C, Turetta M, Bellini S, et al.
CD105(+) cells from Wharton’s jelly show in vitro and in vivo myogenic
differentiative potential. Int J Mol Med. 2006;18:1089–96.
24. Iba Y, Sugimoto Y, Kamei C, Masukawa T. Possible role of mucosal mast cells
in the recovery process of colitis induced by dextran sulfate sodium in rats.
Int Immunopharmacol. 2003;3:485–91.
25. Cooper HS, Murthy SN, Shah RS, Sedergram DJ. Clinicopathologic study of
dextran sulfate sodium experimental murine colitis. Lab Invest.
1993;69:238–49.
26. Islam MS, Murata T, Fujisawa M, Nagasaka R, Ushio H, Bari AM, et al.
Anti-inflammatory effects of phytosteryl ferulates in colitis induced by
dextran sulphate sodium in mice. Br J Pharmacol. 2008;15:812–24.
27. Chance B, Maehly AC. Assay of catalase and peroxidase. Methods Enzymol.
1955;2:764–75.
28. Billings PC, Habres JM, Liao DC, Tuttle SW. Human fibroblasts contain a
proteolytic activity which is inhibited by the Bowman–Birk protease
inhibitor. Cancer Res. 1991;51:5539–43.
29. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D,
et al. Minimal criteria for defining multipotent mesenchymal stromal cells.
The International Society for Cellular Therapy position statement.
Cytotherapy. 2006;8:315–7.
30. Garcia-Bosch O, Ricart E, Panes J. Stem cell therapies for inflammatory
bowel disease – efficacy and safety. Aliment Pharmacol Ther.
2010;32:939–52.31. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate
allogeneic immune cell responses. Blood. 2005;105:1815–22.
32. Gonzalez MA, Gonzalez-Rey E, Rico L, Buscher D, Delgado M.
Adipose-derived mesenchymal stem cells alleviate experimental colitis
by inhibiting inflammatory and autoimmune responses. Gastroenterology.
2009;136:978–89.
33. Gonzalez-Rey E, Andreson P, Gonzalez MA, Rico L, Buscher D, Delgado M.
Human adult stem cells derived from adipose tissue protect against
experimental colitis and sepsis. Gut. 2009;58:929–39.
34. Gnecchi M, Zhang Z, Ni A, Dzau VJ. Paracrine mechanisms in adult stem cell
signaling and therapy. Circ Res. 2009;103:1204–19.
35. Kim HS, Shin TH, Lee BC, Yu KR, Seo Y, Lee S, et al. Human umbilical cord
blood mesenchymal stem cells reduce colitis in. Mice by activating NOD2
signaling to COX2. Gastroenterology. 2013;145:1392–403.
36. Dieleman LA, Ridwan BU, Tennyson GS, Beagley KW, Bucy R, Elson CO.
Dextran sulfate sodium-induced colitis occurs in severe combined
immunodeficient mice. Gastroenterology. 1994;107:1643–52.
37. Axelsson LG, Landstrom E, Goldschmidt TJ, Gronberg A, Bylund-Fellenius
AC. Dextran sulfate sodium (DSS) induced experimental colitis in immuno-
deficient mice: effects in CD4 (+)-cell depleted, athymic and NKcell depleted
SCID mice. Inflamm Res. 1996;45:181–91.
38. Hino K, Saito A, Asada R, Kanemoto S, Imaizumi K. Increased susceptibility to
dextran sulfate sodium-induced colitis in the endoplasmic reticulum stress
transducer OASIS deficient mice. PLoS One. 2014;9, e88048.
39. Cao SS, Zimmermann EM, Chuang BM, Song B, Nwokoye A, Wilkinson
JE, et al. The unfolded protein response and chemical chaperones
reduce protein misfolding and colitis in mice. Gastroenterology.
2013;144:989–1000.
40. Bertolotti A, Wang X, Novoa I, Jungreis R, Schlessinger K, Cho JH, et al.
Increased sensitivity to dextran sodium sulfate colitis in IRE1beta-deficient
mice. J Clin Invest. 2001;107:585–93.
41. Keshavarzian A, Banan A, Farhadi A, Komanduri S, Mutlu E, Zhang Y,
et al. Increases in free radicals and cytoskeletal protein oxidation and
nitration in the colon of patients with inflammatory bowel disease.
Gut. 2003;52:720–8.
42. Lih-Brody L, Powell SR, Collier KP, Reddy GM, Cerchia R, Kahn E, et al.
Increased oxidative stress and decreased antioxidant defenses in mucosa of
inflammatory bowel disease. Dig Dis Sci. 1996;41:2078–86.
43. Arnhold J. Properties, functions, and secretion of human myeloperoxidase.
Biochemistry (Mosc). 2004;69:4–9.
44. Smith JW, Castro GA. Relation of peroxidase activity in gut mucosa to
inflammation. Am J Physiol. 1978;234:R72–9.
45. Medina C, Videla S, Radomski A, Radomski MW, Antolin M, Guarner F,
et al. Increased activity and expression of matrix metalloproteinase-9 in
a rat model of distal colitis. Am J Physiol Gastrointest Liver Physiol.
2003;284:116–22.
46. Ravi A, Garg P, Sitaraman SV. Matrix metalloproteinases in
inflammatory bowel disease: boon or a bane? Inflamm Bowel Dis.
2007;13:97–107.
47. Heimesaat MM, Dunay IR, Fuchs D, Trautmann D, Fischer A, Kühl AA, et al.
The distinct roles of MMP-2 and MMP-9 in acute DSS colitis. Eur J Microbiol
Immunol. 2011;1:302–10.
48. Castaneda FE, Walia B, Vijay-Kumar M, Patel NR, Roser S, Kolachala VL, et al.
Targeted deletion of metalloproteinase 9 attenuates experimental colitis in
mice: central role of epithelial-derived MMP. Gastroenterology.
2005;129:1991–2008.
49. Park DK and Park H. Ethanol Extract of Cordyceps militaris Grown on
Germinated Soybeans Attenuates Dextran-Sodium-Sulfate- (DSS-) Induced
Colitis by Suppressing the Expression of Matrix Metalloproteinases and
Inflammatory Mediators. BioMed Research International, 2013, Article ID
102918.
50. Koelink PJ, Overbeek SA, Braber S, Morgan ME, Henricks PA, Abdul Roda M,
et al. Collagen degradation and neutrophilic infiltration: a vicious circle in
inflammatory bowel disease. Gut. 2014;63:578–87.
51. Kirkegaard T, Hansen A, Bruun E, Brynskov J. Expression and localisation of
matrix metalloproteinases and their natural inhibitors in fistulae of patients
with Crohn’s disease. Gut. 2004;53:701–9.
52. Lozito TP, Tuan RS. Mesenchymal stem cells inhibit both endogenous and
exogenous MMPs via secreted TIMPs. J Cell Physiol. 2011;226:385–96.
53. Perše M, Cerar A. Dextran sodium sulphate colitis mouse model: traps and
tricks. J Biomed Biotechnol. 2012;2012:718617.
Banerjee et al. Stem Cell Research & Therapy  (2015) 6:79 Page 14 of 1454. Freeman HJ. Natural history and long-term clinical course of Crohn's disease.
World J Gastroenterol. 2014;20:31–6.
55. Breider MA, Eppinger M, Gough A. Intercellular adhesion molecule-1
expression in dextran sodium sulfate-induced colitis in rats. Vet Pathol.
1997;34:598–604.
56. Qi XF, Zheng L, Lee KJ, Kim DH, Kim CS, Cai DQ, et al. HMG-CoA reductase
inhibitors induce apoptosis of lymphoma cells by promoting ROS gener-
ation and regulating Akt, Erk and p38 signals via suppression of mevalonate
pathway. Cell Death Dis. 2013;4, e518.
57. Ding W, Yang L, Zhang M, Gu Y. Reactive oxygen species-mediated
endoplasmic reticulum stress contributes to aldosterone-induced
apoptosis in tubular epithelial cells. Biochem Biophys Res Commun.
2012;418:451–6.
58. Malhotra JD, Kaufman RJ. Endoplasmic reticulum stress and oxidative stress:
a vicious cycle or a double-edged sword? Antioxid Redox Signal.
2007;9:2277–93.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
